Vident Advisory’s Genmab GMAB Stock Holding History

Vident Advisory’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.3M	Buy	48,379 +8,672	+22%	+$260K	0.01%	768
2025 Q4	$1.22M	Buy	39,707 +4,060	+11%	+$127K	0.01%	723
2025 Q3	$1.09M	Buy	35,647 +4,165	+13%	+$101K	0.01%	789
2025 Q2	$650K	Buy	31,482 +19,105	+154%	+$392K	0.01%	909
2025 Q1	$242K	Buy	+12,377	New	+$260K	﹤0.01%	1351
2024 Q4	–	Sell	-8,388	Closed	-$205K	–	1487
2024 Q3	$205K	Buy	+8,388	New	+$224K	0.01%	1314
2023 Q4	–	Sell	-8,262	Closed	-$291K	–	1341
2023 Q3	$291K	Buy	+8,262	New	+$315K	0.01%	924

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Vident Advisory's GMAB Position: Q1 2026 in Review

Vident Advisory increased its Genmab (GMAB) stake by 22% in Q1 2026, buying an estimated $260K and bringing the position to 48,379 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #768.

Vident Advisory first reported a position in GMAB in Q3 2023 and has held it in 7 quarters since. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Vident Advisory held 48,379 shares of Genmab worth $1.3M as of Q1 2026.
Vident Advisory bought 8,672 Genmab shares in Q1 2026, an estimated $260K.
Genmab made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #768 holding.
Vident Advisory first reported a position in Genmab in Q3 2023 and has held it in 7 quarters since.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.